clinical trial · NCT06895967
A Study of TAK-881 and HyQvia in Healthy Adults
Takeda·phase1·completed·n = 30
Healthy VolunteersTAK-881HyQviaSC Investigational Needle SetsSC Investigational Needle Sets
brief summary
The main aim of this study is to understand how the body absorbs, processes, and removes (known as pharmacokinetics or PK) TAK-881 and HyQvia, after they are given as a single injection under the skin in healthy adults. Study participants will receive a single dose of TAK-881 or HyQvia on Day 1. During the study, participants will need to stay at the clinic for 8 days followed by 8 ambulatory follow up visits till Day 85.
started
Mar 24, 2025
primary completion
Jul 24, 2025
completion
Jul 24, 2025
last updated
Aug 19, 2025
official title
A Phase 1, Randomized, Open-Label, Pharmacokinetic Trial of TAK-881 and HyQvia in Healthy Adults
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol